This company has been marked as potentially delisted and may not be actively trading. Sinovac Biotech (SVA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesOptions ChainTrendsBuy This Stock SVA vs. MLTX, HCM, ACAD, APLS, AMRX, BHVN, FOLD, MTSR, LGND, and SDGRShould you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include MoonLake Immunotherapeutics (MLTX), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Amneal Pharmaceuticals (AMRX), Biohaven (BHVN), Amicus Therapeutics (FOLD), Metsera (MTSR), Ligand Pharmaceuticals (LGND), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry. Sinovac Biotech vs. MoonLake Immunotherapeutics HUTCHMED ACADIA Pharmaceuticals Apellis Pharmaceuticals Amneal Pharmaceuticals Biohaven Amicus Therapeutics Metsera Ligand Pharmaceuticals Schrödinger MoonLake Immunotherapeutics (NASDAQ:MLTX) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations. Does the media refer more to MLTX or SVA? In the previous week, MoonLake Immunotherapeutics had 13 more articles in the media than Sinovac Biotech. MarketBeat recorded 17 mentions for MoonLake Immunotherapeutics and 4 mentions for Sinovac Biotech. MoonLake Immunotherapeutics' average media sentiment score of 0.76 beat Sinovac Biotech's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 5 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sinovac Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in MLTX or SVA? Sinovac Biotech received 188 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 82.14% of users gave MoonLake Immunotherapeutics an outperform vote while only 67.99% of users gave Sinovac Biotech an outperform vote. CompanyUnderperformOutperformMoonLake ImmunotherapeuticsOutperform Votes6982.14% Underperform Votes1517.86%Sinovac BiotechOutperform Votes25767.99% Underperform Votes12132.01% Is MLTX or SVA more profitable? Sinovac Biotech's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -15.54% -15.09% Sinovac Biotech N/A N/A N/A Do analysts prefer MLTX or SVA? MoonLake Immunotherapeutics presently has a consensus target price of $80.50, indicating a potential upside of 95.96%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in MLTX or SVA? 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation and earnings, MLTX or SVA? MoonLake Immunotherapeutics has higher earnings, but lower revenue than Sinovac Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.89-21.74Sinovac Biotech$448.27M1.44-$99.92MN/AN/A Which has more volatility & risk, MLTX or SVA? MoonLake Immunotherapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. SummaryMoonLake Immunotherapeutics beats Sinovac Biotech on 10 of the 15 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSinovac BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.67M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E RatioN/A7.3822.6318.55Price / Sales1.44241.88397.30103.38Price / Cash38.9565.8538.1834.62Price / Book0.056.476.704.25Net Income-$99.92M$143.68M$3.23B$248.27M Sinovac Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261High Trading VolumeMLTXMoonLake Immunotherapeutics1.5529 of 5 stars$40.00+4.4%$80.50+101.3%+2.9%$2.56BN/A-31.012Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsHCMHUTCHMED1.9657 of 5 stars$13.89+0.9%$19.00+36.8%-19.8%$2.42B$630.20M0.001,760Short Interest ↑ACADACADIA Pharmaceuticals4.2586 of 5 stars$14.38-2.4%$23.93+66.4%-12.6%$2.40B$957.80M18.44510Upcoming EarningsAnalyst ForecastPositive NewsAPLSApellis Pharmaceuticals4.1182 of 5 stars$18.03-0.9%$45.35+151.5%-56.5%$2.26B$781.37M-8.88770Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageAMRXAmneal Pharmaceuticals3.3494 of 5 stars$7.13-3.1%$10.80+51.5%+26.6%$2.21B$2.79B-10.497,600News CoveragePositive NewsBHVNBiohaven3.6265 of 5 stars$20.67+1.5%$62.77+203.7%-43.0%$2.11BN/A-2.21239Upcoming EarningsAnalyst ForecastFOLDAmicus Therapeutics4.3778 of 5 stars$6.71-1.8%$16.75+149.6%-23.1%$2.10B$528.30M-37.28480News CoveragePositive NewsGap DownMTSRMetseraN/A$19.51-0.3%$47.00+140.9%N/A$2.05BN/A0.0081News CoverageHigh Trading VolumeLGNDLigand Pharmaceuticals4.394 of 5 stars$104.81-0.2%$146.43+39.7%+57.2%$2.02B$167.13M41.7680Upcoming EarningsNews CoverageSDGRSchrödinger2.273 of 5 stars$26.19+1.7%$33.00+26.0%+5.1%$1.91B$207.54M-11.19790Upcoming Earnings Related Companies and Tools Related Companies MLTX Alternatives HCM Alternatives ACAD Alternatives APLS Alternatives AMRX Alternatives BHVN Alternatives FOLD Alternatives MTSR Alternatives LGND Alternatives SDGR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SVA Stock Free SVA Stock Alerts